The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171431

Enrollment

Registered

2005-09-15

Start date

2004-11-30

Completion date

2006-05-31

Last updated

2012-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation Predominant, Irritable Bowel Syndrome (IBS-C)

Keywords

IBS-C, female

Brief summary

Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.

Interventions

DRUGTegaserod

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female 18 and older * IBS-C patients diagnosed on the basis of Rome II criteria * Ability to comply with the requirements of the entire study

Exclusion criteria

* Evidence of structural abnormality of the gastrointestinal tract or disease/conditions. * Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy. * Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
To evaluate the effects of tegaserod on motility and small intestinal flow patterns after meal in female patients with IBS-C	—
by using Multiple Intraluminal Impedance	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026